ArticleAmerican journal of cancer research2025
Gut microbiota is associated with the disease characteristics of patients with newly diagnosed diffuse large B-cell lymphoma.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Gut Microbiota in Hematologic Malignancies: Mechanisms, Clinical Associations, and Translational Opportunities.Nutrients · 2026Review
- Indole-3-Carbaldehyde fromResearch (Washington, D.C.) · 2026Article
- Intratumoral Microbiota Correlates with AP-2 Expression: A Pan-Cancer Map with Cohort-Specific Prognostic and Molecular Footprints.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the relationship between the gut microbiota and the biological characteristics of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
methodsThis prospective study included 71 patients with newly diagnosed DLBCL. The microbiota was analyzed using 16S ribosomal DNA sequencing of fecal samples. Blood cytokines, PD-1, and PD-L1 were measured by enzyme-linked immunosorbent assay. Stratified analyses based on clinical characteristics were conducted to investigate correlations between alterations in gut microbiota and key clinicopathological parameters of DLBCL.
resultsIn the analysis of gut microbiota heterogeneity (α diversity index), species abundance was significantly higher in the International Prognostic Index (IPI) < 3 group compared to the IPI ≥ 3 group (high-risk group). Ruminococcus was increased in the IPI ≥ 3 group. Parabacteroides, Ruminococcus, and Eubacterium were increased in the non-germinal center B-cell-like group, while Lachnospira was decreased. Megamonas was significantly increased in the high β2-microglobulin group, while Lactobacillus reuteri and Lachnospira were decreased. In the low CD4+/CD8+ ratio group, Parabacteroides was increased, while Akkermansia was decreased. Patients who failed to achieve complete remission at interim evaluation showed marked increases in Ruminococcus and Alistipes. Extranodal involvement was associated with elevated Alistipes and Enterococcus.
conclusionsThis study identified a potential relationship between the gut microbiota and DLBCL characteristics, highlighting specific gut microbiota organisms that may influence disease development and progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.